NEW YORK (GenomeWeb) – BioTheranostics today announced an agreement with DeNovo Sciences, a circulating tumor cell-based liquid biopsy company, to investigate the feasibility of using BioTheranostics’ proprietary biomarkers for blood-based cancer diagnostics.
According to BioTheranostics, the partners plan to perform proof-of-concept studies using DeNovo's Jetta CTC enrichment and single-cell analysis platform to enable the blood-based detection of undisclosed markers in BioTheranostics portfolio.
If successful, these initial studies could lead to the development of CTC-based liquid biopsy assays.
DeNovo Sciences develops automated systems for rare CTC enrichment and single-cell analysis, namely the label-free Jetta 400 system, which it says performs all the required processing steps to isolate and execute downstream single-cell analysis including immunochemistry, DNA FISH, and mRNA FISH.
“DeNovo Sciences has developed a differentiated platform that will allow us to recover CTCs for molecular characterization utilizing BioTheranostics’ high-resolution cancer biomarkers," Catherine Schnabel, BioTheranostics' chief scientific officer, said in a statement.